HCV drug access remains varied and oft-restricted in Europe
AMSTERDAM Despite the transformative impact of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV), reimbursement for the drugs still faces "considerable restrictions" in Europe, according to research presented Thursday at the International Liver Congress, suggesting that an early challenge for key drugmakers in the space, such as Gilead Sciences Inc. and Abbvie Inc., still endures.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST